News Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
39.5 ^USD	-3.87%		-4.80%	-14.24%

Mar. 11	Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM
Mar. 08	Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting	Apr. 16	GL
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 10	GL
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 04	GL
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days	Mar. 12	GL
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days	Mar. 12	AQ
Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM	Mar. 11
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	Mar. 08	MT
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing	Mar. 08	MT
Xenon Pharmaceuticals : Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission - Form 8-K	Mar. 08	PU
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024	Mar. 05	GL
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024	Mar. 05	AQ
Needham Adjusts Price Target on Xenon Pharmaceuticals to $62 From $50, Maintains Buy Rating	Mar. 01	MT
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk	Mar. 01	MT
Wedbush Raises Xenon Pharmaceuticals' PT to $51 From $46, Continues to See XEN1101 as Differentiated Asset; Maintains Outperform Rating	Mar. 01	MT
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Xenon Pharmaceuticals Q4 Net Loss Widens	Feb. 29	MT
Transcript : Xenon Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Xenon Pharmaceuticals: Q4 Earnings Snapshot	Feb. 29	AQ
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Feb. 29	GL
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Summary

Filters